Pfizer Inc PFE

$28.41 +0.23 (0.82%)

Valuation

Market cap
160,616,816,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.16
Forward PE
9.38
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
34,774,700
Avg volume
36,844,129
Day's range
$28.20 – $28.85
Shares out
5,699,674,000
Stochastic %K
73%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

No headlines yet.

Stocktwits

Biostonk23 Sep 25, 2:31 AM
$PFE back to $26. Nothing in the works
0 replies
PensionPulse Sep 25, 12:50 AM
$VKTX Haha! Viking will not be around next year, never mind 2031! It will be gobbled up by $PFE or $NVO or another BP.
2 replies
GABIRODZ01 Sep 24, 10:24 PM
$ABUS Once we get our victory from $MRNA ’s appeal, the price spike we should be expecting should be within $11.00 - $15.00, right? Anything else above $15.00 is just a plain pipe dream, I’d say. I am planning on selling after $MRNA ‘s appeal decision. If $PFE does not pay immediately, after $MRNA’s settlement (assuming we win), I’d like to start a new position in $ABUS again after the market slashes the price, say, $4.00 - $4.50’s. My belief is that the market makers or whoever it is will do the same thing it happened on 03/03/2026. We should be prepared.
2 replies
JackedNicholson Sep 24, 10:17 PM
$ALT $NVO just scoop it for $10B for God’s sake! You were about to spend that amount for $MTSR and half of their program slashed by $PFE… $10B and you have Pemvidutide franchise…
2 replies
DrMcSavage Sep 24, 9:09 PM
$PFE idk why some of you are complaining the chart actually looks very good and it’s holding up pretty well with the current market situation and seasonality
0 replies
no_cry Sep 24, 8:31 PM
$MRNA when $PFE will be like this 😣
0 replies
Sjs360 Sep 24, 5:44 PM
$PFE the slow bleed 🩸
0 replies
goguryo2000 Sep 24, 5:22 PM
$PFE getting there... 29... come back to where you should be. Perhaps 30 by next week. Gltl
0 replies